Table 2

Study results

CEASR groupRePTA/S groupP value
No of patients; n1417NA
Symptomatic in-stent restenosis; n (%)0 (0)0 (0)1.000
Duration of procedure; mean±SD (min)86.9±23.433.5±13.4<0.001
Residual stenosis after intervention; mean±SD (%)0±020.9±6.7<0.001
Residual stenosis (≥30%) after intervention; n (%)0 (0)4 (23.5)0.040
Stroke/retinal infarction within 30 days after intervention; n (%)0 (0)0 (0)1.000
TIA/amaurosis fugax within 30 days after intervention; n (%)0 (0)0 (0)1.000
Myocardial infarction within 30 days after intervention; n (%)0 (0)0 (0)1.000
Death within 30 days after intervention; n (%)0 (0)0 (0)1.000
Stroke/retinal infarction within 1 year after intervention; n (%)0 (0)0 (0)1.000
TIA/amaurosis fugax within 1 year after intervention; n (%)0 (0)0 (0)1.000
Myocardial infarction within 1 year after intervention; n (%)0 (0)0 (0)1.000
Death within 1 year after intervention; n (%)0 (0)1 (5.9)0.548
Restenosis (≥70%) 1 year after intervention; n (%)1 (7.1)4 (23.5)0.233
Local complications associated with CEASR or rePTA/S within 30 days; n (%)2 (14.3)1 (5.9)0.704
Combined end-point; n (%)3 (21.4)5 (29.4)0.719
  • CAS, carotid artery stenting; CEASR, carotid endarterectomy with stent retrieval; n, number; NA, not available; rePTA/S, repeated percutaneous transluminal angioplasty with or without stenting; TIA, transient ischaemic attack.